IP Library Granted Patent US 7,098,194
Granted Patent B2
US 7,098,194 · App. 10/298,257 · Granted Aug 29, 2006

Composition and method to homogeneously modify or cross-link chitosan under neutral conditions

Assignee: Biosyntech Canada, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,098,194
App. No.
10/298,257
Granted
Aug 29, 2006
Kind
B2
Abstract

In accordance with the present invention there is provided a new composition and method for chemically modifying chitosan, including N-substituting or N-cross-linking, under homogeneous conditions by providing neutral aqueous chitosan solutions with enhanced reactivity. The method comprises the steps of i) preparing a clear aqueous solution of chitosan, said solution comprising 0.1 to 10% by weight of a chitosan, and 0.1 to 20% by weight of at least one buffering agent having a pKa between 6.0 and 7.6, said solution having a pH ranging from 6.8 to 7.2; and ii) dissolving homogeneously at least one reagent into the solution of step a), said reagent being reactive toward amine groups of chitosan; and said reagent being at a concentration from 0.01 to 10% by weight. The chitosan in the aqueous solution is chemically modified or cross-linked by a selective substitution on the amino group of chitosan.

Claims (35)

1. A method for chemically-modifying or cross-linking chitosan under homogeneous conditions, said method comprising the steps of:

a) preparing a clear aqueous solution of chitosan, said solution comprising 0.1 to 10% by weight of a chitosan, and 0.1 to 20% by weight of at least one buffering agent having a pKa between 6.0 and 7.6, said solution having a pH ranging from 6.8 to 7.2; and

b) dissolving homogeneously at least one reagent into the solution of step a), said reagent reacting with amine groups of chitosan; and said reagent being at a concentration from 0.01 to 10% by weight, chemically modifying or cross-linking said chitosan in the aqueous solution.

2. The method of claim 1 further comprising the step of purifying the chemically-modified or cross-linked chitosan.

3. The method of claim 2 , wherein the step of purifying consists of:

a) dialysing the chemically-modified or cross-linked chitosan;

b) precipitating the chitosan obtained in step a), with a basic solution;

c) washing the precipitated chitosan of step b); and

d) air-drying the washed chitosan of step c).

4. The method of claim 1 , wherein said chitosan has a degree of deacetylation between 70% and 100%.

5. The method of claim 1 , wherein said buffering agent is a cell culture biological buffer.

6. The method of claim 5 , wherein the cell culture biological buffer is selected from the group consisting of phosphate salts, glycerophosphate salts, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES); N,N-Bis(2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (DIPSO); N-(2-Hydroxyethyl)piperazine-N′-(4-butanesulfonic acid) (HEPBS); 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES); 2-Morpholinoethanesulfonic acid (MES); 4-(N-Morpholino)butanesulfonic acid (MOBS); 4-Morpholinepropanesulfonic acid (MOPS); β-Hydroxy-4-morpholinepropanesulfonic acid (MOPSO); 2-Bis(2-hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol (BIS-TRIS); and 1,3-Bis[tris(hydroxymethyl)methylamino]propane (BIS-TRIS propane), or a mixture thereof.

7. The method of claim 1 , wherein said reagent is selected from the group consisting of aldehydes, anhydride acids, azides, azolides, carboimides, epoxides, esters, glycidyl ethers, halides, imidazoles, imidates, succinimides, succinimidyl esters, acrylates and methacrylates, or a mixture thereof.

8. The method of claim 1 , wherein said reagent is water-soluble and has at least two reactive groups selected from the group consisting of aldehydes, azides, azolides, esters, glycidyl ethers, halides, imidazoles, imidates, succinimides, succinimidyl esters, acrylates and methacrylates, or a combination thereof.

9. The method of claim 1 , wherein said reagent is poly(ethylene glycol) di-glycidyl ether, poly(ethylene glycol) di-tresylate, poly(ethylene glycol) di-isocyanate, poly(ethylene glycol) di-succinimidyl succinate, poly(ethylene glycol) di-succinimidyl propionate, di-succinimidylester of carboxymethylated poly(ethylene glycol), poly(ethylene glycol) di-benzotriazole carbone, carbonyldimidazole di-functiona-lized poly(ethylene glycol), or poly(ethylene glycol) di-nitrophenyl carbonate.

10. The method of claim 1 , wherein said reagent is a di-functionalized water-soluble polymer selected from the group consisting of poly(alkylene glycol), poly(alkylene oxide), poly(vinyl alcohol) and poly(vinyl pyrrolidone).

11. The method of claim 1 , wherein said reagent is glutaraldehyde, formaldehyde, glyoxal, or a dialdehyde reagent.

12. The method of claim 1 , wherein said reagent has an ester reactive group selected from the group consisting of bi-functional succinimidyl, sulfo-succinimidyl, N-hydro-succinimidyl and N-sulfo-succinimidyl ester group.

13. The method of claim 1 , wherein said reagent has an imidoester reactive group selected from the group consisting of di-methylpimelimidate, di-methyladipimidate, di-methylsuberimidate, and di-methylpropionimidate reactive group.

14. The method of claim 1 , wherein said reagent has a phenylazide, hydrazide, hydroxyphenyl azide or nitrophenyl azide group.

15. The method of claim 1 , wherein the reagent is an acid anhydride.

16. The method of claim 15 , wherein the acid anhydride is selected from the group consisting of acetic anhydride, propionic anhydride and butyric anhydride.

17. The method of claim 1 , wherein the solution of step a) further comprises a pharmaceutical agent, a therapeutic agent or a bioactive agent.

18. The method of claim 1 , wherein the solution of step a) comprises suspended cells.

19. The method of claim 18 , wherein the suspended cells are suspended living mammalian cells.

20. A method of preparation of a chitosan based aqueous gel composition which comprises the steps of:

a) preparing a water-based solution component comprising 0.1 to 10% by: weight of chitosan, having a degree of deacetylation between 70% and 100%, and 0.1 to 20% by weight of a glycerophosphate salt; said solution having a pH in the range between 6.4 and 7.2;

b) preparing a solid component comprising at least a water-soluble methoxy-poly(ethylene glycol) reagent, having a molecular weight between 2,000 and 10,000, said reagent being functionalized with a chemical group reactive with free amine; and

c) mixing homogeneously said solution component and said solid component to form a uniform and homogeneous solution, having 0.01 to 10% by weight of the methoxy-poly(ethylene glycol) reagent,

wherein a homogeneous N-modification or N-grafting of chitosan chains and the formation of a homogeneous uniform aqueous gel occurs.

21. The method of claim 20 , wherein said reagent is selected in a group consisting of methoxy PEG-succinoyl-N-hydroxysuccinimide ester (mPEG-suc-NHS) and methoxy PEG-carboxymethyl-NHS (mPEG-cm-NHS).

22. The method of claim 20 , wherein said composition is liquid prior to said formation of a homogeneous uniform aqueous gel.

23. The method of claim 1 , further comprising the steps of:

c) adding a material of biological origin,

wherein said material of biological origin is selected from the group consisting of autograft, allograft xenograft, crushed bone, demineralized bone powder, solid animal proteins, human proteins, animal living cells and human living cells.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2016
From: PIRAMAL HEALTHCARE (CANADA) LIMITED
To: SMITH & NEPHEW ORTHOPAEDICS AG
Reel/Frame 039937/0787 →
CORRECTIVE TO CORRECT INCORRECT APPLICATION NUMBERS RECORDED ON 10/26/201 REEL/FRAME 025192/0144 INCLUDING 60/733,173; 12/092,498; 61/032,610; 61/262,805; 61/262,808; 61/262,786; 61/262,758; 61/262,792; 12/092,498; 12/919,889. Recorded Apr 6, 2012
From: BIOSYNTEC CANADA INC.
To: PIRAMAL HEALTHCARE (CANADA) LTS.
Reel/Frame 028138/0935 →
ASSET PURCHASE AGREEMENT Recorded Oct 26, 2010
From: BIO SYNTECH CANADA INC.; BIOSYNTECH, INC.
To: PIRAMAL HEALTHCARE (CANADA) LTD.
Reel/Frame 025192/0144 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 013764 FRAME 0459. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR'S NAME WAS INCORRECTLY RECORDED BY THE PTO AS FOUAD H. DABBAR AND SHOULD BE FOUAD DABBARH. Recorded Aug 10, 2004
From: CHENITE, ABDELLATIF; BERRADA, MOHAMMED; CHAPUT, CYRIL; DABBARH, FOUAD; SELMANI, AMINE
To: BIOSYNTECH CANADA, INC.
Reel/Frame 014970/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2003
From: CHENITE, ABDELLATIF; BERRADA, MOHAMMED; CHAPUT, CYRIL; DABBAR, FOUAD H.; SELMANI, AMINE
To: BIOSYNTECH CANADA, INC.
Reel/Frame 013764/0459 →
Continuity (2)
Provisional Application 6033141500 · Nov 15, 2001
Related Publication 20030129730A1 · Jul 10, 2003